Rationale: Osteitis corresponds to a rare but potentially serious complication reported in pediatric population after the application of the Bacillus Calmette-Guerin (BCG) vaccine. In the present study, 3 clinical cases associated with this entity are reported.
Introduction
Bacillus Calmette-Guerin (BCG) corresponds to the live attenuated vaccine used in the prevention of disseminated Tuberculosis in the pediatric population. [1] Despite being considered as a safe vaccine, it has been associated with complications both at local and systemic levels. [2] These complications include ulceration on the site of application, circular adenopathies, osteitis, and dissemination of the disease, which usually occurs in immunocompromised patients. [3] The appearance of the adverse effects depends on multiple factors such as dose, strain, method of application and the immunological status of the vaccinated individual. [4] Post-BCG osteitis is a complication that has been reported in pediatric population, with greater incidence in male than in female population. It can progress through contiguous dissemination, as in the case of humeral osteitis or through hematogenous dissemination with primary extension to epiphysis of long bones due to its wide vascularization. The site of the injury may be independent of the region of application of the vaccine. It usually has a unilateral condition, which suggests a local increase in the vasculature due to a probable traumatic antecedent in the area before the dissemination of the bacillus. [3] At the radiological level, it is characterized by presenting lytic lesions which predominate in the metaphyseal region of the long bones with the presence of periosteal reaction. With regard to the paraclinical tests, it usually shows low response of inflammatory markers, as opposed to the marked elevation of the same in "classic" cases of septic or osteomyelitis arthritis. [5] Post-vaccinal osteitis is a condition rarely detected in pediatric practice due to the limited diffusion and knowledge of this pathological entity, which is why it is usually difficulty to establish the diagnosis. It is estimated that only 25% is diagnosed. The clinical manifestations usually occur after 18 months of the application of the vaccine; nevertheless, the range of clinical appearance varies from few months to 5 years after the application. The lack of response to antimicrobial management, atypical biochemistry, as well as the clinical presentation in a patient suggests the presence of this entity. [2] There are criteria proposed by Foucard & Hjelmsted in 1971 to facilitate the diagnosis of the cases of osteitis associated with the BCG vaccine. [6] 1. Vaccination with BCG in neonatal period. The gold standard to establish the diagnosis corresponds to the biopsy of the lesion through the detection of histopathological changes characterized by the presence of granulomatous reaction and caseous necrosis. Once the diagnosis is established, antituberculosis treatment should be initiated, taking into consideration the results of resistance and susceptibility of the etiological strain. [5] 
Report of cases
This study describes the cases of osteitis secondary to BCG vaccine in immunocompetent patients in a tertiary hospital. Postvaccination osteitis is a condition that is rarely detected in pediatric practice. So, it is fundamental the study of this pathology, its clinical presentation and appropriately diagnosis.
Case 1
The case is a female patient of 21 months old, who presented an increase in volume in the right pelvic limb. The patient has a complete vaccination for her age with application of BCG on April 30 th , 2015. The mother reported a clinical picture of approximately 2 months of evolution, characterized by pain in the bone at the traction of pelvic limb with subsequent claudication to walk. She denies the presence of fever, weight loss, hyporexia or any other symptom.
The patient was then referred to the Oncology Service to begin a procedure of bone tumor management in the anterior tibia of the right leg after denial of the above symptoms, traumatic antecedent or recurrent infection of the airways. Paraclinical studies reported 11.3 g/dL of hemoglobin, 33.8% of hematocrit, 9. ) of platelets, 16 (mm/h) of globular sedimentation rate (GSR) and <0.316 (mg/dL) of C reactive protein (CRP). The Xray of the right pelvic limb depicted a delimited metaphyseal lytic lesion of the proximal right tibia with periosteal reaction and geographical pattern, and increased volume of the soft tissues, as well as metastatic bone series without evidence of other lesions. In magnetic resonance imaging (MRI), compatible chronic granulomatous osteomyelitis lesion was detected, (Fig. 1 ). Based on these evidences, the patient was transferred to Infectious Disease Service to continue his management procedures. The patient was subjected to Purified Peptide Derivative (PPD) test and resulted to be negative with a value of 3x3 mm. Chest X-ray was performed and it ruled out lung compromise (Fig. 2) . High resolution tomography of the lung carried out in search of mediastinal adenopathies suggestive of Tuberculosis was without apparent aggregated lesions. Curettage was done with subsequent application of cryotherapy and graft placement at the site of the lesion. Biopsy of the bone was performed obtaining a culture with histopathological characteristics suggestive of Mycobacterium tuberculosis (Fig. 3) . In genotype analysis of the sample, Mycobacterium bovis (BCG) was identified as the causative agent; thus confirming the association of the lesion with the application of the vaccine in this patient. Sensitivity test performed confirmed the susceptibility of the agent to Isoniazid, Rifampicin, Ethambutol, and Streptomycin. In view of this, antimicrobial scheme based on Clarithromycin 80 mg/kg/day, Ethambutol 20 mg/kg/day, Rifampicin 10 mg/kg/day, and Isoniazid 10 mg/kg/day was started and then began to improve favorably.
Case 2
The 2nd patient is a boy of 2 years and 1 month old, who was referred by the local health center to rule out neoplastic process for presenting a lytic lesion in the epiphysis of left distal femur. ) of platelets. He was subjected to oncological evaluation by the Service of Oncology who ruled out neoplastic processes based on incompatible radiological data. Probable infectious osteomyelitis was suspected and in view of that, empirical treatment based on 200 mg/kg/day of dicloxacillin was started. The patient was later sent to the ward of Pediatric infectious Diseases to continue his treatment procedure. The Xray of the left low limb depicted a large lytic lesion, compromising the internal condyle of the distal epiphysis of the left femur, with conserved cortical edges in the border of the lesion (Fig. 4) . The MRI showed data suggestive of chronic osteomyelitis; hence, bone surgery and curettage were performed and subsequently, graft placement with bioactive bone was undertaken. During the trans-surgical scan, bone tissue biopsy was obtained which reported chronic granulomatous arthritis with caseous necrosis, histopathological data suggestive of M tuberculosis. The staining and polymerase chain reaction of the positive sample for M tuberculosis are reported. On suspecting osteitis secondary to Tuberculosis, it was decided to start a comprehensive approach or procedure based on the following: lumbar radiography without apparent alterations; lung radiography with the presence of 2 bilateral radiopaque lesions in pulmonary hila, suggestive of calcified nodule without another apparent alteration of the pulmonary parenchyma (Fig. 5) ; the parent's radiographies were normal; high resolution computed tomography (CT) of lung of the patient with report of left perihilar ganglionic growth of 13 to 8 mm and presence of a 2 mm nodular lesion on the left lower lobe at the basal level, suggestive of calcified granuloma. Antituberculous treatment based on isoniazid, 10 mg/kg/day; rifampicin, 15 mg/kg/day; pyrazinamide, 25 mg/kg/day and ethambutol, 27 mg/kg/day was started. When M bovis was typified, clarithromycin at 15 mg/kg/day was added in the treatment scheme. Presently, the evolution of the patient is favorable. He is still subjected to procedures to rule out primary immunodeficiency with report of nitroblue tetrazolium negative for chronic granulomatous disease.
Case 3
Case 3 is a female of 3 years and 7 months old. She was admitted in the hospital for presenting intense pain and walking limitation of approximately 5 months of evolution. Analysis of her referral studies consisting on tomographic evidence depicted a lytic lesion on the acetabulum in the iliopubic eminence and anterior-inferior iliac spine with thinning and rapture of the cortical bone.
Moreover, a referral biopsy performed in February, 2016, showed hemorrhagic material with few groups of histiocytes and giant multinucleated Langerhans cells and chronic granulomatous inflammation compatible with Tuberculosis. In view of the above, she was referred to NIP by the National Institute of Rehabilitation for comprehensive evaluation. The BCG immunization record depicted the application of the vaccine at birth in July, 2015.
On being referred to the institute for presenting intense pain with walking limitation, she was attended in the outpatient service of the Orthopedic Department. Extension studies performed before her admission in the institute consisted of bone gammagraphy done on 19 th January, 2016, with report of normal metabolic activity; and bone biopsy, performed on 18 February, 2016, where chronic granulomatous inflammation was appreciated. Upon admission, the approach was complemented with pelvic radiography, performed on 23 rd March, 2016, which showed the presence of lytic lesion on the right acetabulum. Based on the biopsy report, the Infectious Disease Service decided to start treatment based on isoniazid, 10 mg/kg/day; rifampicin, 15 mg/kg/day; pyrazinamide, 20 mg/kg/day; and ethambutol, 25 mg/ kg/day. She was also assessed by the Immunology Service with report of good clinical evolution. The laboratory exams of 6 The BCG vaccine, obtained from the attenuation of M Bovis bacillus, is routinely applied in pediatric population in our country. It is considered a safe vaccine; nevertheless, cases of local and systemic complications including Osteitis have been reported following its application. Some publications, especially in developed countries, have suggested suspending the routine application of the vaccine. However, since Mexico is considered endemic country of Tuberculosis based on the records of World Health Organization (WHO), the rare complications, which have an incidence of approximately 0.39 per 1.000.000 vaccines applied, should not contraindicate its use. [7] The key points in these cases are based on the presence of osteitis associated with the BCG vaccine in 3 immunocompetent patients. Based on literature reported, most patients with osteitis associated with BCG have some type of deficiency at the immunological level that predisposes them to develop this pathological entity.
The importance of this study and the dissemination of these cases consists on identifying the risk factors and clinical characteristics that are associated with them, since they could differ from those seen in immune-compromised patients, taking into account its clinical variability in pediatric population where currently only 25% of the cases are diagnosed. [7] Osteitis due to BCG should be suspected in any child who presents limb edema without evidence of fracture and in cases with compatible radiological characteristics such as metaphyseal lytic lesions and periosteal reaction structures, or histological features associated with M tuberculosis complex.
Medications are the 1st line of treatments for bone Tuberculosis, and the duration of treatment can go between 6 and18 months. [8] Osteitis secondary to BCG vaccine usually has a favorable evolution, especially in immunocompetent patients; however, the involvement of joints, growth discs, and vertebrae increases the risk of presenting long-term sequelae. [9] The lack of response to antimicrobial management as well as the absence of contact with any positive case of tuberculosis and the history of BCG vaccination supports the diagnostic suspicion.
The difficulty of diagnosing this pathological entity in the pediatric population in immunocompetent patients lies on its low incidence (<1%) when compared with the general population. Taking this into account, it is of paramount importance to disseminate the basic aspects and diagnoses of this entity, especially the clinical variability of osteitis by BCG in the pediatric population, with the objective of promoting early detection and timely management so as to reduce morbidity, mortality and the incidence of sequelae or complications associated with it in affected patients.
Conclusion
The adverse effects of BCG vaccination are well documented and are presented in a very low frequency; thus, depicting the benefit in circumstances of an endemic country. Given the large scale application, it should be suspected as the etiological cause of osteitis when this immunization is applied during the neonatal life, with latency period of up to 5 years. Its diagnosis and treatment as well as the identification of early immunocompromise would guarantee the reduction of long-term sequels of the disease.
